|
|
Post by centralcoastinvestor on Jun 14, 2016 14:31:14 GMT -5
My Dad taught me that as you move through life, take moments to "stop and smell the roses." Let's do that now.
I want to remind folks here on the board that Mike C. was hired March 14, 2016. That's less than 3 months ago. I'm just damned impressed that MannKind showed up to the 2016 ADA with such enthusiasm. Because frankly, with just 3 months under his belt, Mike C. could have said lets wait till next year when I am more familiar with the job. And don't forget, he has also assembled a sales team that is ready to rock and roll starting in July.
Am I saying we are out of the woods? Not at all. Just look at the share price and script numbers as a reminder that there is lots of work ahead. I just want to say thank you and enjoy a MannKind accomplishment that is in the books.
So.....Thank you Mike Castagna and MannKind staff for successfully making your presence known at the 2016 ADA Scientific Sessions. Well done. I look forward with great anticipation to what comes next!
|
|
|
|
Post by ilovekauai on Jun 14, 2016 15:29:15 GMT -5
CCI: I agree 100% and now await to see what the new sales force can bring to MNKD, for the rest of this year and beyond. That's where all the marbles are now IMO. It would be wonderful to see those all-important scrip counts begin to rise this fall with MNKD labeling on the boxes, with Sanofi completely out the picture, and don't let the door hit them you know where on the way out! Aloha.
|
|
|
|
Post by babaoriley on Jun 14, 2016 18:56:11 GMT -5
Love your enthusiasm, CCI, but whoever took that job (and I'm glad it was Mike), knew that he/she had to move FAST - one look at the balance sheet and income statement will tell you all you need to know. We have a shot, and I'm pleased Mike is our marksman!
|
|
|
|
Post by patten1962 on Jun 14, 2016 21:11:11 GMT -5
My Dad taught me that as you move through life, take moments to "stop and smell the roses." Let's do that now. I want to remind folks here on the board that Mike C. was hired March 14, 2016. That's less than 3 months ago. I'm just damned impressed that MannKind showed up to the 2016 ADA with such enthusiasm. Because frankly, with just 3 months under his belt, Mike C. could have said lets wait till next year when I am more familiar with the job. And don't forget, he has also assembled a sales team that is ready to rock and roll starting in July. Am I saying we are out of the woods? Not at all. Just look at the share price and script numbers as a reminder that there is lots of work ahead. I just want to say thank you and enjoy a MannKind accomplishment that is in the books. So.....Thank you Mike Castagna and MannKind staff for successfully making your presence known at the 2016 ADA Scientific Sessions. Well done. I look forward with great anticipation to what comes next! We are in much better shape then we were in January of this year! No one is talking Bk. We have a sales team. Running 2 shifts in Danbury. Ramping up for something. I feel very good about my investment! |
|
|
|
Post by mnholdem on Jun 14, 2016 22:52:37 GMT -5
Love your enthusiasm, CCI, but whoever took that job (and I'm glad it was Mike), knew that he/she had to move FAST - one look at the balance sheet and income statement will tell you all you need to know. We have a shot, and I'm pleased Mike is our marksman! It speaks volumes to me that of Castagna's first two hires that report to him directly, one is an experienced payer negotiator. Afrezza must get tier coverage that is equivalent or better than RAA insulin. I think that the new studies published at ADA-2016, along with an aggressive pricing/rebate strategy, will prove to be keys in convincing Plan Benefits Managers to recognize Afrezza as an excellent treatment - if not better - than existing prandial insulin. Payer negotiations are going well, according to Castagna. That's encouraging. What's more encouraging to me is that Mike recognized what baba points out (above) that MannKind "had to move FAST", because payers often update their formularies a few times a year at most. You don't want miss those formulary review deadlines. Mike hired a pro to deal with tier negotiations immediately after he himself was hired. |
|
|
|
Post by centralcoastinvestor on Jun 14, 2016 23:50:56 GMT -5
Love your enthusiasm, CCI, but whoever took that job (and I'm glad it was Mike), knew that he/she had to move FAST - one look at the balance sheet and income statement will tell you all you need to know. We have a shot, and I'm pleased Mike is our marksman! I agree with you that Mike knew he had to move fast. Because he is the right person for the job, he has made the most of the time given to him. Kudos should extend to Matt for hiring him. But as we have all seen, just because someone looks good (Brandicourt) does not mean they will perform as advertised. I'm very pleased with what I have witnessed so far. Management is performing at a high level. Next up, selling Afrezza. This is where the rubber meets the road and will mean survival of the company. |
|
|
|
Post by inittowinit on Jun 15, 2016 3:46:58 GMT -5
Mr. C knows what we have here. its a matter of connecting the dots. He can and will connect those dots as long as we can stay solvent. I personally believe if anyone can do this it will be Mike. I'm staying win or lose....GLTAL!
|
|
|
|
Post by mbseeking on Jun 15, 2016 5:21:25 GMT -5
Yes. This is the penultimate MNKD back to the wall moment.
Innovative product that customers love. Good team now in place. All we need is little of the last ingredient: luck.
|
|
|
|
Post by rockstarrick on Jun 15, 2016 10:19:25 GMT -5
Thanks Mike and the rest of the mnkd team !! Now let's blow the doors off this thing !!!
|
|
|
|
Post by victoria on Jun 15, 2016 10:40:41 GMT -5
|
|
|
|
Post by novafett on Jun 15, 2016 13:44:19 GMT -5
I'm curious as I'm not terribly familiar with the ADA. What kind of developments, if any, should we expect out of the ADA. Special announcements, etc. or is it just basically another form of face to face marketing?
|
|
|
|
Post by centralcoastinvestor on Jun 16, 2016 0:50:39 GMT -5
I'm curious as I'm not terribly familiar with the ADA. What kind of developments, if any, should we expect out of the ADA. Special announcements, etc. or is it just basically another form of face to face marketing? Although I'm no expert, I will take a shot at explaining what I believe the 2016 ADA Scientific Sessions did for MannKind. 1. Showed the national and international diabetic professional community that Afrezza was not going away, even though Sanofi terminated the partnership. It was mentioned from more than one source that some physicians stopped prescribing Afrezza to new patients because they thought Afrezza was going to disappear after Sanofi dropped Afrezza. 2. Essentially this event is the super bowl for diabetic healthcare professionals. If a company is going to publish anything of significance related to diabetes, this is the place to do it. So it was a great thing that 6 studies were presented from MannKind. Of most significance, was the study concerning the timing of onset and departure from the body of Afrezza. I do think it turned a few heads. 3. Obviously, another big point of the conference are contacts. I'm pretty sure there are now dozens of leads for Endos to be followed up by the new sales force once launch begins in July. Also, I'm pretty sure Matt was making corporate contacts at lunches and cocktail sessions. It was good for MannKind to be present because that's what the big players do. That is all I got at the moment. Perhaps others can add to the list. |
|
|
|
Post by novafett on Jun 16, 2016 8:48:46 GMT -5
Hey CCI, thanks so much for your reply. That really helps a ton and I feel like I have a better understanding of what the ADA is for and about now. Mucho Gracias!
|
|
|
|
Post by dictatorsaurus on Jun 16, 2016 11:43:06 GMT -5
We are at $1 right now. Hats should come off when we see Afrezza scripts go up and company aggressively moving ahead.
|
|
|
|
Post by centralcoastinvestor on Jun 16, 2016 12:15:21 GMT -5
We are at $1 right now. Hats should come off when we see Afrezza scripts go up and company aggressively moving ahead. I completely understand what you are saying. In my opinion, it doesn't hurt to celebrate the little things along the journey. Could Mnkd still go belly up? Yes they could. I don't think it's likely, but it is possible. Next up, launch. I'm excited to see what Mike C. and his team will do. And then, it's all about the script numbers. |
|
